Dr. Filbin is an emergency physician and director of clinical research in the Department of Emergency Medicine at Massachusetts General Hospital (MGH) in Boston and an associated member of the Broad Institute of MIT and Harvard. His research involves early detection and management of septic shock. Over the past decade, Dr. Filbin has been a key investigator in U.S. National Institutes of Health–funded multicenter clinical trials, led sepsis quality improvement efforts, and investigated early sepsis detection strategies. He cochairs the Sepsis Early Detection Think Tank at MGH with the mission of joining translational researchers and clinical investigators within the Harvard community to encourage novel diagnostic and therapeutic approaches in sepsis. Dr. Filbin received a bachelor’s degree in aeronautics and aerospace engineering from the University of Washington in Seattle. He embarked on a career in engineering at the National Aeronautics and Space Administration in Houston, Texas, before attending medical school at Baylor College of Medicine in Houston. He completed a residency in emergency medicine at the combined Harvard Affiliated Emergency Medicine Residency program and received a Master’s in clinical epidemiology from the Harvard School of Public Health in Boston.

Dr. Mehta is an oncologist, immunologist, and mathematician who is currently a postdoctoral researcher in Nir Hacohen and Eric Lander’s labs at the Broad Institute of MIT and Harvard, and a clinical fellow in hematology/oncology at the Dana-Farber Cancer Institute/Partners CancerCare. Prior to his current position, he obtained his undergraduate degrees at Duke University studying mathematics and chemistry, his M.D. at the David Geffen School of Medicine at the University of California, Los Angeles, and his Ph.D. in biology and bioengineering at the California Institute of Technology under the guidance of Nobel laureate David Baltimore. He completed his internal medicine residency at Massachusetts General Hospital in the Stanbury Physician-Scientist Pathway program. His current interests lie at the intersection of tumor immunology and computational biology, with a focus on building new tools for single-cell genomics studies in tumors.

Dr. Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor, before joining Science/AAAS in 2006. Currently, Dr. Sanders is the Director and Senior Editor for Custom Publishing for the journal Science and Program Director for Outreach.